...
机译:三聚体,V2缺失的HIV-1包膜糖蛋白疫苗可激发有效的中和抗体,但在人类志愿者中中和的范围有限。
Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Georgia;
Department of Medicine, Miriam Hospital and Alpert Medical School of Brown University, Providence, Rhode Island;
Fred Hutchinson Cancer Research Center, Seattle, Washington;
Department of Surgery, Duke University School of Medicine, Durham, North Carolina;
Department of Surgery, Duke University School of Medicine, Durham, North Carolina;
Fred Hutchinson Cancer Research Center, Seattle, Washington;
Fred Hutchinson Cancer Research Center, Seattle, Washington;
Fred Hutchinson Cancer Research Center, Seattle, Washington;
Fred Hutchinson Cancer Research Center, Seattle, Washington;
Fred Hutchinson Cancer Research Center, Seattle, Washington;
Department of Internal Medicine, St. Louis University School of Medicine, Missouri;
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland;
Novartis Vaccines and Diagnostics, Cambridge, Massachusetts;
Novartis Vaccines and Diagnostics, Cambridge, Massachusetts;
Fred Hutchinson Cancer Research Center, Seattle, Washington;
机译:一种三聚体,缺失V2的HIV-1包膜糖蛋白疫苗可引发有效的中和抗体,但在人类志愿者中产生的中和范围有限。
机译:重复接种三聚体HIV-1包膜糖蛋白对兔引起的中和抗体反应的分析
机译:交叉反应性HIV-1中和性单克隆抗体,可通过筛选针对人包膜糖蛋白(gp140)的免疫人噬菌体文库进行筛选,该包膜糖蛋白从具有广泛HIV-1中性抗体的患者(R2)中分离。
机译:双特异性多价HIV-1中和抗体效果抑制了SHIV感染
机译:HIV-1包膜抗原决定簇的选择和分析,用于设计可诱导广泛中和抗体的疫苗
机译:三聚体V2缺失的HIV-1包膜糖蛋白疫苗可激发有效的中和抗体但在人类志愿者中中和的范围有限。
机译:三聚体,V2缺失的HIV-1包膜糖蛋白疫苗可激发有效的中和抗体,但在人类志愿者中中和的范围有限。